1652 주식 개요 투자 지주 회사인 푸센 제약 유한회사는 중화인민공화국에서 의약품을 연구, 개발, 제조, 판매하는 회사입니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Fusen Pharmaceutical Company Limited 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Fusen Pharmaceutical 과거 주가 현재 주가 HK$0.80 52주 최고치 HK$1.39 52주 최저치 HK$0.71 베타 0.54 1개월 변경 -13.04% 3개월 변경 사항 -20.00% 1년 변경 사항 -42.45% 3년 변화 -34.96% 5년 변화 -83.47% IPO 이후 변화 -68.50%
최근 뉴스 및 업데이트
There's Reason For Concern Over Fusen Pharmaceutical Company Limited's (HKG:1652) Price Dec 18
Eltrombopag Olamine Tablets Developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Obtains the Approval for Marketing from the National Medical Products Administration of China Oct 22
Fusen Pharmaceutical Company Limited Announces Acceptance of Application for Consistency Evaluation of Nicardipine Hydrochloride Injection Oct 17
First half 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.022 profit in 1H 2023) Oct 01
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2024 Aug 22
Fusen Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 29, 2024 Aug 20 더 많은 업데이트 보기
There's Reason For Concern Over Fusen Pharmaceutical Company Limited's (HKG:1652) Price Dec 18
Eltrombopag Olamine Tablets Developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Obtains the Approval for Marketing from the National Medical Products Administration of China Oct 22
Fusen Pharmaceutical Company Limited Announces Acceptance of Application for Consistency Evaluation of Nicardipine Hydrochloride Injection Oct 17
First half 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.022 profit in 1H 2023) Oct 01
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2024 Aug 22
Fusen Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 29, 2024 Aug 20
Fusen Pharmaceutical Company's Subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces Acceptance of Clinical Trial Application for ``SY617'' Jul 12
New minor risk - Market cap size Jun 27
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky May 21
Fusen Pharmaceutical Company Limited, Annual General Meeting, May 28, 2024 Apr 28
CEO & Executive Director recently bought HK$224k worth of stock Apr 25 Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I) Apr 05
Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27% Mar 31
Full year 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.046 loss in FY 2022) Mar 30
Fusen Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 19
First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022) Oct 01
First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022) Aug 31
Fusen Pharmaceutical Company Limited to Report Q2, 2023 Results on Aug 29, 2023 Aug 18
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023 Aug 13
Executive Chairman recently bought HK$84k worth of stock Apr 17
CEO & Executive Director recently bought HK$1.0m worth of stock Apr 01
Full year 2022 earnings released: CN¥0.046 loss per share (vs CN¥0.022 profit in FY 2021) Mar 30
Executive Chairman recently bought HK$1.1m worth of stock Jan 31
Executive Chairman recently bought HK$918k worth of stock Jan 10
CEO & Executive Director recently bought HK$375k worth of stock Jan 03
Executive Chairman recently bought HK$791k worth of stock Dec 19
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky Dec 14
Executive Chairman recently bought HK$2.3m worth of stock Nov 27
Less than half of directors are independent Nov 16
CEO & Executive Director recently bought HK$2.2m worth of stock Nov 10
Executive Chairman recently bought HK$2.0m worth of stock Nov 02
CEO & Executive Director recently bought HK$2.0m worth of stock Oct 25
CEO & Executive Director recently bought HK$658k worth of stock Oct 11
CEO & Executive Director recently bought HK$79k worth of stock Sep 22
CEO & Executive Director recently bought HK$1.9m worth of stock Sep 14
CEO & Executive Director recently bought HK$1.9m worth of stock Sep 10
First half 2022 earnings released: CN¥0.01 loss per share (vs CN¥0.057 profit in 1H 2021) Sep 02
Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Six Months Ended June 30, 2022 Aug 30
Fusen Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022 Aug 21
Fusen Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 29, 2022 Aug 17
CEO & Executive Director recently bought HK$157k worth of stock Aug 01
CEO & Executive Director recently bought HK$1.9m worth of stock Jul 15
CEO & Executive Director recently bought HK$1.9m worth of stock Jun 11
Fusen Pharmaceutical Company Limited Declares Final Dividend for the Year Ended 31 December 2021 Jun 01
Less than half of directors are independent Apr 27
Investor sentiment improved over the past week Dec 22
CEO & Executive Director recently bought HK$856k worth of stock Dec 22
CEO & Executive Director recently bought HK$2.1m worth of stock Dec 12
Investor sentiment deteriorated over the past week Dec 07
First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020) Sep 26
Investor sentiment deteriorated over the past week Sep 19
Investor sentiment improved over the past week Sep 03
Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly Sep 02
First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020) Aug 25
Investor sentiment deteriorated over the past week Jun 23
Fusen Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2020 May 27
Investor sentiment deteriorated over the past week May 12
Full year 2020 earnings released: EPS CN¥0.089 (vs CN¥0.067 in FY 2019) Apr 25
Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly Apr 02
Full year 2020 earnings released: EPS CN¥0.09 (vs CN¥0.067 in FY 2019) Apr 02
Investor sentiment improved over the past week Mar 29
Fusen Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021 Mar 20
A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns Mar 06
New 90-day low: HK$4.17 Feb 24
We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide Feb 08
Company Secretary has left the company Feb 03
Fusen Pharmaceutical Company Limited Announces Executive Changes, with Effect from 29 January 2021 Jan 31
Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals? Jan 18
Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet? Dec 28
Investor sentiment deteriorated over the past week Dec 22
Investor sentiment deteriorated over the past week Dec 18
Investor sentiment deteriorated over the past week Dec 14
What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition Dec 07
Market bids up stock over the past week Dec 07
New 90-day high: HK$6.00 Nov 20
If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns Nov 20
Market bids up stock over the past week Nov 05
New 90-day high: HK$4.69 Nov 03
Market bids up stock over the past week Oct 23
First half earnings released Sep 16
New 90-day high - HK$3.78 Sep 02
First half earnings released Sep 01
Fusen Pharmaceutical Company Limited to Report First Half, 2020 Results on Aug 31, 2020 Aug 22 주주 수익률 1652 HK Pharmaceuticals HK 마켓 7D -1.2% -4.0% -2.4% 1Y -42.4% -11.3% 16.2%
전체 주주 수익률 보기
수익률 대 산업: 1652 지난 1년 동안 -11.3 %를 반환한 Hong Kong Pharmaceuticals 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: 1652 지난 1년 동안 16.2 %를 반환한 Hong Kong 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is 1652's price volatile compared to industry and market? 1652 volatility 1652 Average Weekly Movement 5.9% Pharmaceuticals Industry Average Movement 6.3% Market Average Movement 8.2% 10% most volatile stocks in HK Market 16.5% 10% least volatile stocks in HK Market 3.7%
안정적인 주가: 1652 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: 1652 의 주간 변동성 ( 6% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 투자 지주 회사인 푸센제약은 중화인민공화국에서 의약품을 연구, 개발, 제조, 판매하는 기업입니다. 이 회사의 제품 포트폴리오에는 쌍황련 경구액과 쌍황련 주사제로 구성된 쌍황련 기반 감기약, 열 제거 및 해독 경구액, 니카르디핀 염산염 주사제 및 기타 제품이 포함됩니다. 또한 심뇌혈관, 혈압 및 혈당 감소, 강장, 기 조절, 빈혈, 항균 및 항염증, 위장관, 거담 기침 카테고리 제품도 제공합니다.
자세히 보기 Fusen Pharmaceutical Company Limited 기본 사항 요약 Fusen Pharmaceutical 의 수익과 매출은 시가총액과 어떻게 비교하나요? 1652 기본 통계 시가총액 HK$591.44m 수익(TTM ) -HK$95.54m 수익(TTM ) HK$453.34m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 1652 손익 계산서(TTM ) 수익 CN¥425.49m 수익 비용 CN¥199.23m 총 이익 CN¥226.26m 기타 비용 CN¥315.93m 수익 -CN¥89.67m
주당 순이익(EPS) -0.12 총 마진 53.18% 순이익 마진 -21.08% 부채/자본 비율 67.0%
1652 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/01/02 07:03 장 마감 주가 2025/01/02 00:00 수익 2024/06/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Fusen Pharmaceutical Company Limited 0 애널리스트 중 0 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
